Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Immunotherapeutics
100%
Multimers
100%
Complement Activation
100%
Safety Assessment
100%
Immunoconjugates
100%
Therapeutic Drug Monitoring
100%
Immunotherapy Strategies
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
60%
Tumor
60%
CD20
40%
High Efficacy
40%
Local Complementation
20%
Technical Platform
20%
Tumor Cell Targeting
20%
Therapeutic Monoclonal Antibody
20%
Concept Development
20%
Direct Cytotoxicity
20%
Unmet Medical Need
20%
Lymphoma Cells
20%
Lymphoma
20%
Tumor Cells
20%
Solid Tumors
20%
Development Program
20%
C4BP
20%
Biopharmaceuticals
20%
Clinical Practice
20%
Factor H Binding Protein
20%
Therapeutic Efficacy
20%
NK Cell Activity
20%
Standard of Care
20%
Tumor Model
20%
Increasing Prevalence
20%
Further Development
20%
Conventional Chemotherapy
20%
Multivalent
20%
Cell-based
20%
Cell-to-cell
20%
Development Strategy
20%
Xenograft Model
20%
Innovative Strategies
20%
Phagocytosis
20%
New Therapeutic Approaches
20%
Immunotherapeutic Strategies
20%
Liquid Tumors
20%
Therapeutic Potency
20%
Chemotherapy-free Regimen
20%
Target Function
20%
Immunology and Microbiology
Immunotherapy
100%
Complement Activation
100%
Antibody Conjugate
100%
Tumor Cell
40%
CD20
40%
Factor H
20%
Xenograft
20%
Natural Killer Cell
20%
Prevalence
20%
Cell Phagocytosis
20%
Monoclonal Antibody
20%
Cytotoxicity
20%
Concept Formation
20%
Cell Activation
20%
Lymphoma Cell
20%
In Vitro
20%
Pharmacology, Toxicology and Pharmaceutical Science
Antibody Conjugate
100%
Immunotherapy
100%
Chemotherapy Regimens
66%
Tumor Model
33%
Monoclonal Antibody
33%
Solid Malignant Neoplasm
33%
Complement Factor H
33%
Prevalence
33%
Cytotoxicity
33%
Biopharmaceutical
33%